Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity
- 46 Downloads
Background and Objective
A significant number of people worldwide consume khat on daily basis. Long term of khat chewing has shown negative impact on several organ systems. It is likely that these people are co-administered khat preparations and conventional medication, which may lead to khat-drug interactions. This study aimed to reveal the inhibitory potencies of khat ethanol extract (KEE) and its major active ingredient (cathinone) on human cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 enzymes activities, which are collectively responsible for metabolizing 70–80% clinically used drugs.
In vitro fluorescence-based enzyme assays were developed and the CYP enzyme activities were quantified in the presence and absence of KEE and cathinone employing Vivid® CYP450 Screening Kits.
KEE inhibited human CYP2C9, CYP2D6, and CYP3A4 enzyme activities with IC50 of 42, 62, and 18 μg/ml. On the other hand, cathinone showed negligible inhibitory effect on these CYPs. Further experiments with KEE revealed that KEE inhibited CYP2C9 via non-competitive or mixed mode with Ki of 14.7 μg/ml, CYP2D6 through competitive or mixed mode with Ki of 17.6 μg/ml, CYP3A4 by mixed inhibition mode with Ki of 12.1 μg/ml.
Khat-drug interactions are possible due to administration of clinical drugs metabolized by CYP2C9/CYP2D6/CYP3A4 together with khat chewing. Further in vivo studies are required to confirm our findings and identify the causative constituents of these inhibitory effects.
Compliance with Ethical Stanadards
This project was supported by the University of Nottingham Malaysia Campus final year project grant BMS/FYP/2017-06, BMS-PY5, and University of Malaya research Grant RG539-13HTM.
Conflict of interest
All authors have no conflicts of interest to declare.
- 12.Alfaifi H, Abdelwahab SI, Mohan S, Elhassan Taha MM, Syame SM, Shaala LA, et al. Catha edulis Forsk. (Khat): evaluation of its antidepressant-like activity. Pharmacogn Mag Wolters Kluwer Medknow Publ. 2017;13:S354–8.Google Scholar
- 14.Afify EA, Alkreathy HM, Ali AM, Alfaifi HA, Khan LM. Characterization of the antinociceptive mechanisms of Khat extract (Catha edulis) in mice. Front Neurol Front. 2017;8:69.Google Scholar
- 15.Sadeg M, Al-Awar A, Abdullah M, Al-Eryan Y. Effect of the ethanolic extract of Catha edulis leaves on the electrical activity of some brain centers of male rabbits. Int Biol Biomed J. 2017;3:133–7.Google Scholar
- 17.Life technologies. Vivid ® CYP450 Screening Kits User Guide. 2012. https://assets.thermofisher.com/TFS-Assets/LSG/manuals/Vivid_CYP450_Screening_Kits_man.pdf. Accessed 25 Sept 2018.
- 27.Grimm SW, Einolf HJ, Hall SD, He K, Lim H-K, Ling K-HJ, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos. 2009;37:1355–70.CrossRefPubMedCentralGoogle Scholar
- 35.Meyer MR, Vollmar C, Schwaninger AE, Wolf EU, Maurer HH. New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC–MS and LC-high-resolution MS and their detectability in urine. J Mass Spectrom. 2012;47:253–62.CrossRefPubMedCentralGoogle Scholar
- 36.Meyer MR, Du P, Schuster F, Maurer HH. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC–MS and LC-high-resolution MS and its detectability in urine by GC–MS. J Mass Spectrom. 2010;45:1426–42.CrossRefPubMedCentralGoogle Scholar